Cargando…
Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
To assess whether beta-blocker use is associated with cardiovascular events and mortality in patients with heart failure with preserved ejection fraction (HFpEF), this study analyzed the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial data using Co...
Autores principales: | Tsujimoto, Tetsuro, Kajio, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015007/ https://www.ncbi.nlm.nih.gov/pubmed/29934526 http://dx.doi.org/10.1038/s41598-018-27799-y |
Ejemplares similares
-
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020) -
Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017) -
Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis
por: Liu, Feng, et al.
Publicado: (2014) -
The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction
por: Xu, Xizhen, et al.
Publicado: (2019) -
Association of Systemic Trimethyllysine With Heart Failure With Preserved Ejection Fraction and Cardiovascular Events
por: Wei, Haoran, et al.
Publicado: (2022)